Surmodics (SRDX) Projected to Post Quarterly Earnings on Wednesday

Surmodics (NASDAQ:SRDX) is anticipated to release its Q4 2025 results before the market opens on Wednesday, November 5th. Analysts expect Surmodics to post earnings of ($0.19) per share and revenue of $30.14 million for the quarter. Surmodics has set its FY 2025 guidance at -0.350–0.200 EPS.Interested persons may review the information on the company’s upcoming Q4 2025 earningreport for the latest details on the call scheduled for Wednesday, November 12, 2025 at 12:30 PM ET.

Surmodics (NASDAQ:SRDX) last posted its earnings results on Friday, August 8th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.27. The company had revenue of $29.57 million during the quarter, compared to analysts’ expectations of $28.04 million. Surmodics had a negative return on equity of 2.99% and a negative net margin of 14.59%. On average, analysts expect Surmodics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Surmodics Price Performance

SRDX stock opened at $27.43 on Monday. The business has a fifty day moving average of $30.51 and a two-hundred day moving average of $30.80. The company has a quick ratio of 3.10, a current ratio of 3.91 and a debt-to-equity ratio of 0.27. The stock has a market cap of $392.19 million, a price-to-earnings ratio of -22.30 and a beta of 1.31. Surmodics has a 52-week low of $26.00 and a 52-week high of $40.38.

Analyst Ratings Changes

Several research firms have issued reports on SRDX. Barrington Research reissued a “market perform” rating on shares of Surmodics in a research note on Monday, August 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Surmodics in a research note on Wednesday, October 8th. Finally, Zacks Research raised Surmodics to a “hold” rating in a research note on Tuesday, August 12th. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $43.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Qube Research & Technologies Ltd boosted its position in shares of Surmodics by 1.2% during the second quarter. Qube Research & Technologies Ltd now owns 393,984 shares of the company’s stock worth $11,705,000 after buying an additional 4,799 shares during the period. Balyasny Asset Management L.P. boosted its holdings in Surmodics by 0.9% in the second quarter. Balyasny Asset Management L.P. now owns 271,682 shares of the company’s stock valued at $8,072,000 after purchasing an additional 2,290 shares during the period. Millennium Management LLC boosted its holdings in Surmodics by 71.6% in the first quarter. Millennium Management LLC now owns 206,487 shares of the company’s stock valued at $6,304,000 after purchasing an additional 86,143 shares during the period. Lighthouse Investment Partners LLC boosted its holdings in Surmodics by 200.1% in the second quarter. Lighthouse Investment Partners LLC now owns 94,772 shares of the company’s stock valued at $2,816,000 after purchasing an additional 63,187 shares during the period. Finally, Norges Bank purchased a new position in Surmodics in the second quarter valued at $939,000. 96.63% of the stock is currently owned by hedge funds and other institutional investors.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).